RecruitingPhase 2NCT07104812
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Studying NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Irina Bancos, MDMayo Clinic
- Intervention
- Osilodrostat 1 MG(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2027
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Collaborators
RECORDATI GROUP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07104812 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07361874IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionUniversity of Texas Southwestern Medical Center
- RECRUITINGPHASE4NCT07247058Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)Johns Hopkins University
- ACTIVE NOT RECRUITINGPHASE2NCT06106295Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
See all trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor →